RDHL - RedHill to get US patent linked to bacterial infection drug
- RedHill Biopharma ( NASDAQ: RDHL ) said that the U.S. Patent and Trademark Office (USPTO) issued a notice of allowance for a patent covering RHB-204's oral fixed-dose combination, methods treating pulmonary Mycobacterium avium Complex (MAC) disease.
- The patent will also cover kits comprising a supply of fixed-dose combination products for treating pulmonary MAC disease.
- The company added that RHB-204 is currently undergoing a phase 3 trial in the U.S. as the first stand-alone standard of care first-line therapy for Non-tuberculosis Mycobacteria (NTM) disease caused by MAC infection.
- MAC is a group of bacteria causing lung diseases.
- The patent is expected to protect RHB-204 through 2041.
- RedHill noted that it is advancing discussions with several prospective partners for RHB-204 in multiple territories.
- RDHL +2.51% to $0.18 premarket Jan. 26
For further details see:
RedHill to get US patent linked to bacterial infection drug